S S Hasan1, K M Teh2, S I Ahmed3, D W K Chong4, H C Ong5, B Naina6. 1. The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia. Electronic address: shahzad_pharmacy@yahoo.com. 2. International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia. Electronic address: teh_khai_mei@hotmail.com. 3. International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia. Electronic address: sia194@yahoo.com. 4. Monash University, Sunway Campus Malaysia, Jalan Lagoon Selatan, Bandar Sunway 46150, Malaysia. Electronic address: david.chong@med.monash.edu.my. 5. International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia. Electronic address: ohchin87@yahoo.com. 6. General Hospital Kuala Lumpur, Jalan Pahang, Kuala Lumpur 50586, Malaysia. Electronic address: basariahnaina@yahoo.com.
Abstract
OBJECTIVES: To investigate association between quality of life (QoL) and International Normalized Ratio (INR) control, with the secondary aim of assessing QoL using generic and anticoagulation-specific, the Short Form Health Survey (SF-12) and the Duke Anticoagulation Satisfaction Scale (DASS). STUDY DESIGN: This study assessed anticoagulation related QoL at three time intervals in two groups of patients on long-term warfarin therapy. METHODS: Data of 326 randomly sampled patients (163 patients each in DASS and SF-12 groups) who had been on warfarin therapy for at least one year at anticoagulation clinics were analysed. QoL was assessed at three time intervals: at the start, six months and one year of warfarin therapy. Indications and target INR ranges and subjects INR values were recorded. Time in Therapeutic Range (TTR) was estimated for four subject subgroups, based on target ranges of INR for clustered indications. RESULTS:Of the total, 43% of the subjects were aged between 50 and 64 years, and 51% were female. DASS assessed subjects older than 35 years perceived significant decrease in overall mean scores of anticoagulation related QoL, whilst all SF-12 assessed subjects perceived an increase in QoL. The mean percentage days in range for all INR target range subgroups did not exceed more than 60% but there was only a weak correlation (Rs = 0.104, P > 0.05) between INR control and overall QoL. CONCLUSION:Malaysian urban outpatients onwarfarin treatment longer than one year report a significant overall decrease in QoL, as measured using a validated condition-specific instrument. These patients appeared to adapt well to lifestyle limitations imposed by long-term anticoagulation.
RCT Entities:
OBJECTIVES: To investigate association between quality of life (QoL) and International Normalized Ratio (INR) control, with the secondary aim of assessing QoL using generic and anticoagulation-specific, the Short Form Health Survey (SF-12) and the Duke Anticoagulation Satisfaction Scale (DASS). STUDY DESIGN: This study assessed anticoagulation related QoL at three time intervals in two groups of patients on long-term warfarin therapy. METHODS: Data of 326 randomly sampled patients (163 patients each in DASS and SF-12 groups) who had been on warfarin therapy for at least one year at anticoagulation clinics were analysed. QoL was assessed at three time intervals: at the start, six months and one year of warfarin therapy. Indications and target INR ranges and subjects INR values were recorded. Time in Therapeutic Range (TTR) was estimated for four subject subgroups, based on target ranges of INR for clustered indications. RESULTS: Of the total, 43% of the subjects were aged between 50 and 64 years, and 51% were female. DASS assessed subjects older than 35 years perceived significant decrease in overall mean scores of anticoagulation related QoL, whilst all SF-12 assessed subjects perceived an increase in QoL. The mean percentage days in range for all INR target range subgroups did not exceed more than 60% but there was only a weak correlation (Rs = 0.104, P > 0.05) between INR control and overall QoL. CONCLUSION: Malaysian urban outpatients on warfarin treatment longer than one year report a significant overall decrease in QoL, as measured using a validated condition-specific instrument. These patients appeared to adapt well to lifestyle limitations imposed by long-term anticoagulation.
Authors: Emilio Márquez-Contreras; Nieves Martell-Claros; Vicente Gil-Guillén; Mariano De la Figuera-Von Wichmann; Eugenio Sánchez-López; Ines Gil-Gil; Sara Márquez-Rivero Journal: Qual Life Res Date: 2017-01-06 Impact factor: 4.147
Authors: Muhammad Shahid Iqbal; Yaman Walid Kassab; Fahad I Al-Saikhan; Ziyad S Almalki; Abdul Haseeb; Muhammad Zahid Iqbal; Majid Ali Journal: Saudi Pharm J Date: 2020-06-25 Impact factor: 4.330
Authors: Nicholas W Carris; Andrew Y Hwang; Steven M Smith; James R Taylor; Karen Sando; Jason Powell; Eric I Rosenberg; Marc S Zumberg; John G Gums; Eric A Dietrich; Katherine Vogel Anderson Journal: J Thromb Thrombolysis Date: 2016-11 Impact factor: 2.300